

Supplementary Table 3. Evidence table about the eradication rate of standard triple therapy in *Helicobacter pylori* infection

Study	Indication	Subjects no.	Eradication regimen	Confirmative test	Eradication rate ITT	Eradication rate PP
Choi et al. (2007) [65]	PU, NUD	576	OAC7-148 PAC7-140 RAC7-140 EAC7-148 TOTAL-576	CLO, Histology	OAC7-64.9 (96/148) PAC7-69.3 (97/140) RAC7-69.3 (97/140) EAC7-70.3 (104/148) TOTAL-68.4 (394/576)	OAC7-80.7 (96/119) PAC7-76.9 (97/121) RAC7-81.5 (97/119) EAC7-82.6 (104/121) TOTAL-82.1 (394/480)
Kim et al. (2007) [66]	PU	598	PAC7-337 PAC14-261	UBT	PAC7-71.2 (240/337) PAC14-75.5 (197/261)	PAC7-83.6 (239/286) PAC14-86.6 (194/224)
Kim et al. (2008) [68]	PU	463	LFT7-115 LFT14-117 LAC7-119 LAC14-112	UBT	LFT7-76.5 (88/115) LFT14-76.9 (90/117) LAC7-78.2 (93/119) LAC14-80.4 (90/112)	LFT7-81.6 (80/98) LFT14-82.0 (73/89) LAC7-82.2 (83/101) LAC14-85.9 (79/92)
Kim et al. (2008) [67]	PUD, NUD	186	OAC14-93 OAC(QID)14-93	UBT, CLO	OAC14-91.4 (85/93) OAC(QID)14-89.2 (83/93)	OAC14-92.1 (82/89) OAC(QID)14-90.8 (79/87)
Kim et al. (2008) [70]	HP infected patients	347	PAC7-179 PAC7 + YOGT-168	UBT	PAC7-72.1 (129/179) PAC7 + YOGT-79.2 (133/168)	PAC7-78.7 (129/164) PAC7 + YOGT-87.5 (133/152)
Choi et al. (2008) [69]	HP infected patients	158	OAC7-81 SEQ10-77	UBT	OAC7-71.6 (58/81) SEQ10-77.9 (60/77)	OAC7-76.6 (58/76) SEQ10-85.7 (60/70)
Jung et al. (2008) [71]	PUD	38	OAC7 + O3WK-14 OAC7-12 O3WK + OAC7-12	CLO, Histology	OAC7 + O3WK-14-50.0 (7/14) OAC7-12-66.7 (8/12) O3WK + OAC7-75.0 (9/12)	OAC7 + O3WK-87.5 (7/8) OAC7-80.0 (8/10) O3WK + OAC7-90.0 (9/10)
Kim et al. (2008) [72]	HP infected patients	257	LAC7-129 LAC7 + ECABET-128	UBT	LAC7-72.1 (93/129) LAC7 + ECABET-78.9 (101/128)	LAC7-78.8 (93/118) LAC7 + ECABET-88.6 (101/114)
Song et al. (2010) [74]	HP infected patients	991	PAC7-331 PAC7 + PROB-330 PAC7 + PROB + MUCOPRO TECTIVE-330	UBT	PAC7-71.6 (237/331) PAC7 + PROB-80.0 (264/330) PAC7 + PROB + MUCOPRO TECTIVE-82.1 (271/330)	PAC7-80.0 (237/296) PAC7 + PROB-85.4 (264/309) PAC7 + PROB + MUCOPRO TECTIVE-84.9 (271/319)
Lee et al. (2010) [73]	HP infected patients	492	LAC7-247 RAC7-245	UBT	LAC7-74.9 (185/247) RAC7-66.5 (163/245) TOTAL-70.7 (348/492)	LAC7-79.1 (185/234) RAC7-71.2 (163/229) TOTAL-75.2 (348/463)
Kim et al. (2011) [75]	HP infected patients	409	PAC14-204 SEQ10-205		PAC14-75.0 (153/204) SEQ10-85.9 (176/205)	PAC14-85.0 (153/180) SEQ10-92.6 (176/190)
Choi et al. (2011) [76]	PUD	363	OAC7-99 OAL7-98 OALR7-98		OAC7-77.8 (77/99) OAL7-65.3 (64/98) OALR7-74.5 (73/98)	OAC7-85.6 (77/90) OAL7-73.6 (64/87) OALR7-80.2 (73/91)
Chung et al. (2012) [77]	PUD	159	OAC10-80 SEQ10-79		OAC10-58.7 (47/80) SEQ10-75.9 (60/79)	OAC10-67.6 (46/68) SEQ10-86.8 (59/68)
Choi et al. (2012) [78]	PUD	460	RAC7-115 RAC10-115 RAC14-115 SEQ10-115	UBT, Histology	RAC7-70.4 (81/115) RAC10-74.7 (86/115) RAC14-80.0 (92/115) SEQ10-75.6 (87/115)	RAC7-75.7 (81/107) RAC10-81.9 (86/105) RAC14-84.4 (92/109) SEQ10-82.0 (87/106)

Supplementary Table 3. Continued

Study	Indication	Subjects no.	Eradication regimen	Confirmative test	Eradication rate ITT	Eradication rate PP
Park et al. (2012) [79]	HP infected patients	348	SEQ10-162 RAC7-164		SEQ10-77.8 (126/162) RAC7-62.2 (102/164)	SEQ10-87.9 (126/132) RAC7-76.0 (102/125)
Oh et al. (2012) [80]	PUD, HP infected patients	246	SEQ10-116 RAC7-130		SEQ10-79.3 (92/116) RAC7-63.0 (82/130)	SEQ10-81.9 (91/111) RAC7-64.5 (82/127)
Kim et al. (2012) [81]	PUD	208	LAC14-104 LA(TID)14-104	UBT, CLO	LAC14-74.0 (77/104) LA(TID)14-67.3 (70/104)	LAC14-82.8 (77/93) LA(TID)14-78.4 (69/88)
Lee et al. (2013) [82]	PUD	1232	TAILORED-218 RAC7-308 RAM7-308	UBT	TAILORED-80.7 (176/218) RAC7-69.5 (214/308) RAM7-71.1 (219/308)	TAILORED-91.2 (176/193) RAC7-75.9 (214/282) RAM7-79.1 (219/277)
Kim et al. (2013) [83]	PUD	270	LAC7-135 CONCO5-135	UBT	LAC7-72.6 (98/135) CONCO5-80.7 (109/135)	LAC7-85.2 (98/115) CONCO5-91.4 (106/116)
Heo et al. (2014) [84]	PUD	348	LAC10-174 CONCO10-174	UBT	LAC10-70.7 (123/174) CONCO10-78.7 (137/174)	LAC10-78.4 (120/153) CONCO10-88.7 (133/150)
Park et al. (2014) [85]	EGC, dysplasia	114	PAC7-57 PRE-SUSCEP-57	UBT	PAC7-71.9 (41/57) PRE-SUSCEP-94.7 (54/57)	PAC7-73.2 (41/56) PRE-SUSCEP-96.4 (54/56)
Lee et al. (2014) [86]	PUD, NUD, GC	332	PAC7-115 SEQ10-111 SEQ15-106	UBT, CLO	PAC7-64.3 (74/115) SEQ10-72.1 (80/111) SEQ15-80.2 (85/106)	PAC7-68.5 (74/108) SEQ10-78.4 (80/102) SEQ15-89.5 (85/95)
Lee et al. (2015) [87]	PUD, HP gastritis	680	PAC7-170 PAM7-170 SEQ10-170 CONCO7-170	UBT	PAC7-64.1 (109/170) PAM7-68.8 (117/170) SEQ10-70.7 (119/170) CONCO7-79.4 (135/170)	PAC7-76.2 (109/143) PAM7-84.2 (117/139) SEQ10-70.7 (119/170) CONCO7-79.4 (135/143)
Bang et al. (2015) [88]	PUD, NUD	112	PAC7-55 PAC7 + PRONASE-57	UBT	PAC7-76.4 (42/55) PAC7 + PRO-NASE-56.1 (32/57)	PAC7-87.5 (42/48) PAC7 + PRONASE-68.1 (32/47)
Chung et al. (2016) [89]	PUD, EGC, MALT lymphoma	517	PAC10-171 SEQ10-170 CONCO10-176		PAC10-83.0 (142/171) SEQ10-88.8 (151/170) CONCO10-93.2 (164/176)	PAC10-82.8 (106/128) SEQ10-89.5 (119/133) CONCO10-94.4 (135/143)
Kim et al. (2016) [90]	PUD	601	PAC7-295 SEQ5-306	UBT, CLO, histology	PAC7-70.8 (209/295) SEQ5-82.4 (252/306)	PAC7-76.9 (206/268) SEQ5-88.8 (247/278)

ITT, intention-to-treat; PP, per protocol; PU, peptic ulcer; NUD, non-ulcer dyspepsia; OAC, omeprazole, amoxicillin, clarithromycin; PAC, pantoprazole, amoxicillin, clarithromycin; RAC, rabeprazole, amoxicillin, clarithromycin; EAC, esomeprazole, amoxicillin, clarithromycin; CLO, campylobacter-like organism; UBT, urea breath test; LFT, lafutidine; LAC, labeprazole, amoxicillin, clarithromycin; PUD, peptic ulcer disease; QID, quarter in die; HP, *Helicobacter pylori*; YOGT, yogurt; SEQ, sequential therapy; O3WK, omeprazole 3 weeks; ECABET, ecabet sodium; PROB, probiotics; MUCOPROTECTIVE, mucoprotective agent; OALR, omeprazole, amoxicillin, levofloxacin, rifabutin; LA, levofloxacin, amoxicillin; TID, ter in die; TAILORED, tailored therapy; RAM, rabeprazole, amoxicillin, metronidazole; CONCO, concomitant therapy; EGC, early gastric cancer; PRE-SUSCEP, pre-susceptibility test; GC, gastric cancer; PAM, proton pump inhibitor (PPI), amoxicillin, metronidazole; PRO-NASE, pronase (protease); MALT, mucosa-associated lymphoid tissue.